Platelet Levels of High- and Mega-Dose Methylprednisolone Treatment in Acute Immune Thrombocytopenia

A 16-year-old male presented with the complaints of oral submucosal bleeding and purpura

Ali Ayçiçek

2015

Scholarcy highlights

  • A 16-year-old male presented with the complaints of oral submucosal bleeding and purpura
  • Informed consent was obtained for High-dose methylprednisolone and Mega-dose methylprednisolone treatment
  • High-dose methylprednisolone was initiated at a dose of 1000 mg/day for 3 days followed by 750 mg/day for 4 days, with each dose administered orally early in the morning
  • HDMP treatment has been used as a therapeutic choice in childhood acute immune thrombocytopenic purpura in Turkey for a long time
  • The term ‘HDMP’ was used for this kind of methylprednisolone administration initially, but it was later changed to MDMP since ‘HDMP’ was used for 4-10 mg/kg doses in the literature
  • It is reported that MDMP treatment differs from conventional corticosteroid and pulse methylprednisolone administration, by dose and the time of administration
  • I would like to emphasize Mega-dose methylprednisolone treatment for these patients, which seems to be the most effective approach in the treatment of this disorder regardless of patient weight

Need more features? Save interactive summary cards to your Scholarcy Library.